CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. - Wikidata - wikimedia - TriplyDB

CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.

CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.

http://www.wikidata.org/entity/Q37342767

about

Thrombotic microangiopathy with targeted cancer agents Cancer-associated thrombotic microangiopathy A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.Epitope mapping and key amino acid identification of anti-CD22 immunotoxin CAT-8015 using hybrid β-lactamase display The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.Delivery of ricin toxin a-chain by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.Targeting malignant B cells with an immunotoxin against ROR1 Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Immunoconjugates in the management of hairy cell leukemia.Antibody-based therapeutics for the treatment of human B cell malignancies Linked-in: design and efficacy of antibody drug conjugates in oncology Hairy cell leukemia - immunotargets and therapies Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies Advances in the treatment of hematologic malignancies using immunoconjugates Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Class A β-lactamases as versatile scaffolds to create hybrid enzymes: applications from basic research to medicine.Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.High efficient expression of a functional humanized single-chain variable fragment (scFv) antibody against CD22 in Pichia pastoris.Bacterial Toxins for Cancer Therapy.Clinical targeting recombinant immunotoxins for cancer therapy Camelid VH H affinity ligands enable separation of closely related biopharmaceuticals Development and scale-up of a commercial fed batch refolding process for an anti-CD22 two chain immunotoxin.ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.Anticancer Activity of Bacterial Proteins and Peptides.

P2860

Q24635904-02E96556-92A3-4E84-BA81-E837FC50D1F6 Q26738984-58E77C27-238D-410B-AEA0-3CDE4235A811 Q33758660-385BE73B-F52B-482F-9135-9047DD2AC5B1 Q33772436-8F31BAB9-84D1-417E-82B3-2867E60668CF Q33840201-9810BD7F-EE59-45C1-8858-A0236100E44C Q33993918-8F4EF39F-4E0C-4140-8FD2-F86D36038205 Q35230663-78BBB336-DB00-4E28-93AD-2C7F13E6C333 Q35446035-25A6427F-52C3-47AA-9403-7CFF1CAE3FED Q35446333-34C489C2-797C-4ECE-9239-08FDE47A1309 Q35918856-8FD26380-B34A-45C0-97A2-212DF0673410 Q35969887-B768520B-D3CD-4BA4-A430-D2E7455D39BD Q36058502-3DABECFA-5AA8-43B0-9788-01A392BF05F7 Q36273796-978F4665-1BA8-49F5-B137-16FF05C42206 Q36328016-8898498B-95D1-4527-8C97-50E4351B8782 Q36907540-3FC7CF74-4008-44CB-B304-F5DB3ABCB79C Q37029370-C1FD6370-0BC4-4D07-95C5-6BBE41CDFCEF Q37031666-76FFF7BE-9238-4155-89E2-F057A18F2949 Q37165245-014A1319-7EF3-4A37-8710-43A6EB578860 Q37697843-559C3F0E-19B9-453A-9374-E94948F9B2D2 Q37913356-82B2B752-26E0-4708-A92E-F3FA37B16588 Q38143097-096767C7-BCEB-4486-9C12-7E4E44060CB5 Q38932868-200C7860-4BC9-4CC6-BBD4-1CFB98F32666 Q38954962-07376E5F-D2DC-43BA-A949-50E5F6B49DD8 Q40101895-53364D64-1FEC-4529-B23D-C017D609AA79 Q41149227-BA5126A0-F54E-4A98-8472-DDE55CBD7BC2 Q42318888-C08E5C7D-7B97-4225-BC79-430BEA18E78B Q43090431-A9040420-75CB-4740-B6F7-37014E38B891 Q47197303-9584E9A5-CC9B-4882-B9A2-7B3408176494 Q51031788-A368F5F4-BAC8-4A83-8E87-3AF7E1D9359D Q53689854-D3E50EFF-5116-4CF1-9606-8205F0F86374

P2860

CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.

http://www.wikidata.org/entity/Q37342767

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CAT-8015: a second-generation ...... sing hematologic malignancies.

@en

CAT-8015: a second-generation ...... sing hematologic malignancies.

@nl

type

label

CAT-8015: a second-generation ...... sing hematologic malignancies.

@en

CAT-8015: a second-generation ...... sing hematologic malignancies.

@nl

prefLabel

CAT-8015: a second-generation ...... sing hematologic malignancies.

@en

CAT-8015: a second-generation ...... sing hematologic malignancies.

@nl

P1433

Q37342767-3F5AD088-F721-469A-9554-E42C3577C34C

P1476

Q37342767-463C0242-C9B8-43CC-B571-95D2570FC4C2

P2093

Q37342767-02511574-7890-4E37-8132-D7B47431C158

Q37342767-85890A74-4D66-4956-8C16-080CF4EC08BC

Q37342767-89917B48-858F-4C64-A8B3-816AFD11441C

Q37342767-9497E48A-891C-45B5-A043-98E3540394A1

Q37342767-9577362C-1332-4084-83C1-E37E0B6CD9B1

Q37342767-C09E8BF9-6E9E-40F8-8DA5-B84FF5B00FF8

Q37342767-FEF3A9F7-EB44-429D-8077-554C42F3D9CA

P2860

Q37342767-26B4F33E-963A-4A72-8FF1-19C2E67381A1

Q37342767-2E3C694E-2626-468E-98BA-CCD91764E46E

Q37342767-3F1EEF10-56C1-4954-9071-8F48A9420988

Q37342767-43F9B60E-844D-4A31-BA55-077B68121ACB

Q37342767-551A3963-DF35-4D39-9B26-4ADCAE5A53FE

Q37342767-5CAADFBC-56D9-4BEA-B0C2-E7B78147B678

Q37342767-602FAE7E-58FD-4660-B365-8FA0AF4211DB

Q37342767-69D57BB6-FF2A-45AF-96FB-CE07EBC45537

Q37342767-76293019-87DE-43CB-948C-9DEE8B8BB86D

Q37342767-7C408B46-EF61-4F01-9673-BAE873E20A22

P304

Q37342767-831204A5-8778-4975-BFF1-9C2AEE5BDE8C

P31

Q37342767-7F5DCC27-E1E5-41E2-AB23-6B7E130D0B23

P356

Q37342767-4B48864C-BD1A-441C-9AED-C0431BB6B686

P407

Q37342767-84A87130-2884-4F61-BDD7-BEB0CF853BC8

P433

Q37342767-29333C03-A2FA-4ACB-B4D8-53A1EB01A85A

P478

Q37342767-B4992CBC-2EA8-43A0-843E-9AE932EDAAA1

P577

Q37342767-28EA2403-CD35-4FFC-B17D-D05023A8040D

P698

Q37342767-198917F9-ACE3-43E0-B63A-58AE04F2C73E

P921

Q37342767-D3899A42-3560-4C59-9FB3-EAC5B8006B58

P932

Q37342767-78E8704B-7FEC-43BB-9F39-29C00EC3FC0C

P356

1078-0432.CCR-08-1456

P1433

Clinical Cancer Research

P1476

CAT-8015: a second-generation ...... sing hematologic malignancies.

@en

P2093

Ira Pastan

http://www.w3.org/2001/XMLSchema#string

Judy A Fox

http://www.w3.org/2001/XMLSchema#string

Peter Yeung

http://www.w3.org/2001/XMLSchema#string

Ralph F Alderson

http://www.w3.org/2001/XMLSchema#string

Robert J Kreitman

http://www.w3.org/2001/XMLSchema#string

Ronald Herbst

http://www.w3.org/2001/XMLSchema#string

Tianling Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Improving the efficacy of antibody-based cancer therapies

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Clinical studies with targeted toxins in malignant glioma.

Newer monoclonal antibodies for hematological malignancies.

Structure, function, and regulation of Pseudomonas aeruginosa exotoxin A.

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

Phase I immunotoxin trial in patients with B-cell lymphoma.

P304

832-839

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1456

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19188153

http://www.w3.org/2001/XMLSchema#string

P921

P932

2742326

http://www.w3.org/2001/XMLSchema#string